Verastem Inc VSTM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Verastem Oncology to Report Third Quarter 2026 Financial Results on November 5, 2026
-
Verastem Oncology Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants
-
Verastem Oncology Announces Planned Chief Executive Officer Transition and Succession Plan
-
VS-7375 Demonstrates Robust Anti-Tumor Activity Across Advanced KRAS G12D-Mutant Cancers, Highlighted by 50% Confirmed ORR in 2L Pancreatic Ductal Adenocarcinoma and Two Complete Responses in 2L+ Disease (One Confirmed)
-
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Verastem Oncology Announces New RAMP 201 Molecular Profiling and External Control Arm Analyses Describing Outcomes for Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at IGCS 2026
-
Verastem Oncology Announces Publication in Gynecologic Oncology of Two-Year Median Follow-Up Data from RAMP 201 Study of AVMAPKI® FAKZYNJA® CO-PACK (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer
-
KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034
Trading Information
- Previous Close Price
- $10.00
- Day Range
- $9.76–10.15
- 52-Week Range
- $3.43–10.82
- Bid/Ask
- $9.90 / $10.27
- Shares Outstanding
- 121.50M
- Market Cap
- $1.23B
- Volume/Avg
- 2,669 / 3M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 10.25
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 102
- Website
- https://www.verastem.com
Valuation
|
Metric
|
VSTM
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 18.28 |
Price/Sales | 10.25 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
VSTM
|
|---|---|
Quick Ratio | 2.12 |
Current Ratio | 2.25 |
Interest Coverage | −138.86 |
Quick Ratio
VSTM
Profitability
|
Metric
|
VSTM
|
|---|---|
Return on Assets (Normalized) | −74.46% |
Return on Equity (Normalized) | −374.59% |
Return on Invested Capital (Normalized) | −125.00% |
Return on Assets
VSTM
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|t<ClFc | LOCK|Zzg$g | $132B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|r^q!X& | LOCK|%d?< | $84B | |||
| Moderna Inc
MRNA
| LOCK|m<SQzzF | LOCK|^Gh | $83B | |||
| argenx SE ADR
ARGX
| LOCK|hHQp&LV | LOCK|d< | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|^k$dXh | LOCK|#m | $42B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|jg!<wrc | LOCK|$N!Lz | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|X%H!Tf<b | LOCK|Yy$$ | $29B | |||
| Incyte Corp
INCY
| LOCK|<>!nMKx | LOCK|V&h | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|S#@M&r | LOCK|%k | $22B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|&<$JF<g | LOCK|CFJ | $14B |
United States